

24 May - 30 May 2010

COMPANY SPOTLIGHT

- **Clovis Oncology** (Boulder) and **Avila Therapeutics** (Waltham, MA) announced an agreement for the development and commercialization of Avila's epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, currently in pre-clinical development for the treatment of non-small cell lung cancer (NSCLC). Under the terms of the agreement, Avila and Clovis Oncology will collaborate on the pre-clinical development of the EMSI product candidate. Clovis Oncology will be fully responsible for all aspects of development and commercialization, including development of companion diagnostics to prospectively identify patients with clinically-arising resistance mutations of the EGFR.
- **MicroPhage** (Longmont) announced the launch of its new diagnostic platform at the 110th Annual General Meeting of the American Society for Microbiology (ASM) in San Diego. The Company's initial commercial product is designed to rapidly identify *Staphylococcus aureus* ("staph") bacteria as well as determine methicillin resistance (MRSA) or susceptibility (MSSA) in suspected cases of bloodstream infections in as little as five hours. The product is CE-Marked for sale outside the United States and U.S. Food and Drug Administration (FDA) review is pending.
- **Gevo** (Denver) a renewable chemicals and advanced biofuels company, announced that it has closed a round of funding led by German specialty chemicals company LANXESS. Existing investors also participated in the round. In connection with this financing, the Company also announced that Dr. Ron Commander, head of the LANXESS Group's Butyl Rubber Business Unit, will join the Gevo Board of Directors. The LANXESS investment comes after the French oil and gas giant Total invested in the company.
- **miRagen Therapeutics** (Boulder) announced that its Director of Biology, Eva van Rooij, Ph.D., gave the keynote lecture at The Ohio State University College of Pharmacy's Research Day & Symposium. The lecture centered on miRNAs of interest to miRagen and the chemistries involved in their manipulation.
- **Pico-Tesla** (Littleton) cited data from an in vivo study recently completed at the Univ. of Oklahoma's Heart Rhythm Institute that suggests extremely low-level electromagnetic fields (EMFs) can prevent and reverse involuntary remodeling of the heart by terminating and preventing atrial fibrillation (A-Fib). The principal investigator for the study was Benjamin J. Scherlag, Ph.D., and Sunny S. Po, M.D., Ph.D. of the Heart Rhythm Institute, University of Oklahoma Health Sciences Center.
- **UMB** (Kansas City, MO) and **Commerce Bank** (St. Louis and Kansas City, MO) were ranked Numbers 2 and 3 respectively on Forbes list of America's Best Banks. [Click here to read more.](#)

SQUARE PEGS

- **The Colorado BioScience Association** and statewide business groups joined Governor Bill Ritter, Jr. as he signed two executive orders on Thursday, May 27. The orders are designed to further the growth of emerging technology companies within the state of Colorado. The first executive order calls for an online "Investment Opportunity Index" to classify opportunities for capital investment within the bioscience and cleantech industries. The Index will be located on the website of the Colorado Office of Economic Development, and will serve as an information clearinghouse for potential investors and partners. The second order calls for the formation and quarterly meeting of a Roundtable on Venture Capital, which includes the Governor. This group will serve at the direction of the Governor's Office of Economic Development and International Trade as an advisory group supporting Colorado's efforts to encourage investment in companies located in Colorado.

- **C2D2**, a program of CSU Ventures, Inc. (CSUV) funded by a grant from the State of Colorado Office of Economic Development and International Trade, invites researchers to submit drug discovery-related proposals to be funded through C2D2 sponsored grants. The grants (up to \$50K/project) incentivize collaborative partnerships and are intended for short term (e.g. 3-9 month) projects. *See the attached RFP for more information.*
- On Friday, May 21, the IRS released guidance on the **Therapeutic Discovery Tax Credit**, describing the process by which firms can apply to have their research projects certified as eligible for the credit. Companies may submit applications for certification beginning June 21, 2010, and applications must be postmarked no later than July 21, 2010. As part of the review process for research projects, the Department of Health and Human Services (HHS) will evaluate each project for its potential to produce new therapies or reduce health care costs. Only projects that show a reasonable potential to meet these goals will be certified as eligible for the credit. The IRS will issue certifications by the end of October based on the determinations made by HHS. *Please see the attached document provided by BIO for more information, or contact Jamison Meredith, Senior Manager, Business Tax Services at Ernst & Young for specific questions, or assistance with filing at jamison.meredith@ey.com.*
- **The Medical Career Collaborative (MC2) program** at The Children's Hospital provides high school students from disadvantaged socio-economic backgrounds an opportunity to gain experience and exposure in the fields of health, medicine and bioscience. This two year program includes a paid internship at Children's and help with college preparation. Over the last ten years, 200 students have enrolled in MC2 and all have graduated from high school. The program is currently seeking cosponsors from the bioscience community. *Please see the attached document for more information.*
- **BioSurplus**, a leading provider of equipment management services and pre-owned laboratory instruments to the life sciences industry, is part of the BIO Business Solutions program, in which the CBSA is a partner. BioSurplus offers solutions for every stage of the equipment life cycle – from acquisition, inventory management, service and repair to resale. Utilizing the deep in-lab experience of its team and its proprietary industry-specific equipment management software (e-Quip™), BioSurplus tailors solutions to fit the unique needs of its customers. CBSA members can enjoy the following benefits:
 - 5% credit or 1% cash rebate on equipment purchases made each year
 - Credit equal to 10% of the buyer's premium for items purchased through a BioSurplus auction
 - 5% credit or 1% cash rebate on net consignment proceeds issued each year to sellers
 - 10% discount on setup fees for e-Quip enabled services
 - 30-day money back guarantee on most purchased equipment

UPCOMING EVENTS

- **CBSA's Bioscience Bogey Tournament, presented by Accera Pharma**, will take place on June 14 at the Fox Hollow Golf Course. Several sponsorship opportunities are still available. Visit <http://www.cobiosciencebogey.com> for more information or to register.
- **Polsinelli Shughart** will hold a webinar on June 9 during which top health care public policy attorneys will discuss health care reform as it relates to the medical device community. [Click here](#) to register.
- **Fitzsimons Redevelopment Authority, Fitzsimons BioBusiness Partners, Colorado BioScience Association & University of Colorado** will be holding a Core Labs Show to showcasing the valuable resources available in the Core Labs at University of Colorado and National Jewish Health. The event will take place on June 15 from 9:30-12:30pm at the Bioscience Park Center in Aurora. *Please see the attached PDF for more info.*
- **BioMARC**, the regional training center for product translation at **Colorado State University**, will be holding a lunch-and-learn short course sponsored by GE Healthcare on Tuesday, June 29, on "Applying Filtration, WAVE Reactor, and Chromatography Single-Use Technologies to BioProcessing". [Click here for more info or to register.](#)

- **Denver Public Schools** announced that it will be hosting a citywide career fair for its eighth graders. The event will be held on Wednesday, October 20, 2010 at the National Western Complex off of I-70 and Brighton Blvd. The primary objective of the event is to expose the students to the vast scope of careers available to them and to help them plan for their future. The school system is seeking companies to exhibit - *Please see the attached documents for more information or to register your company to take part.*

SAVE THE DATE: Please join us for the **Roche Colorado Corporation Peptide Symposium (RCCPS)** on September 14 – 16, 2010 at the St. Julian Hotel and Spa in Boulder, CO. The program highlights include; Peptides in the Clinic; Peptide Drug Delivery; Emerging Technologies; Advances in Peptide Chemistry; and, Quality by Design in Peptides. The following link www.rccps.org, and attachments will provide additional information on the conference and sponsorship opportunities. We look forward to showcasing Colorado as a leader in Peptides at this conference and hope you will be able to join us! Please see attached flyer for information on sponsorship opportunities.